Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28330001 | 0.83 | HSD17B10 (0.59) | KDM4EHSD17B10ALOX15TSHRSMN1; SMN2 | |
| SCHEMBL7344719 | 0.82 | GAA (0.42) | SMN1; SMN2POLBMEN1KMT2AALDH1A1 | |
| SCHEMBL28510183 | 0.79 | KMT2A (0.41) | KDM4EALOX15TSHRSMN1; SMN2MEN1 | |
| SCHEMBL16826426 | 0.79 | SIGMAR1 (0.41) | HSD17B10MEN1KMT2A | |
| SCHEMBL19711907 | 0.78 | KMT2A (0.35) | SMN1; SMN2KMT2AALDH1A1LMNAMAPT | |
| SCHEMBL28864606 | 0.77 | PDK1 (0.38) | ALDH1A1L3MBTL1 | |
| SCHEMBL28864623 | 0.77 | PDK1 (0.38) | ALDH1A1L3MBTL1 | |
| SCHEMBL28507620 | 0.77 | PIK3CD (0.42) | KDM4ESMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL28513535 | 0.77 | LTA4H (0.32) | KDM4ETSHRPOLB | |
| SCHEMBL28864650 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116768972-A | Preparation method of carfilzomib intermediate | 重庆药友制药有限责任公司 | 2023-09-19 | — | — | CN | disclosed |
| CN-115244047-A | Indazole derivative and application thereof in medicine | 四川海思科制药有限公司 | 2022-10-25 | — | — | CN | disclosed |
| US-6903097-B2 | Heterocycle carboxamides as antiviral agents | PHARMACIA & UPJOHN COMPANY (US) | 2005-06-07 | — | — | US | disclosed |
| US-20040142928-A1 | Heterocycle carboxamides as antiviral agents | BUNDY GORDON L (US) | 2004-07-22 | — | — | US | disclosed |
| US-20030207880-A1 | Heterocycle carboxamides as antiviral agents | BUNDY GORDON L (US) | 2003-11-06 | — | — | US | disclosed |
| US-6559145-B2 | Herpes virus | PHARMACIA & UPJOHN COMPANY | 2003-05-06 | — | — | US | disclosed |
| US-20020025960-A1 | Heterocycle carboxamides as antiviral agents | PHARMACIA & UPJOHN COMPANY | 2002-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142928-A1 | Heterocycle carboxamides as antiviral agents | ZC3HAV1, ZC3HAV1L, HDAC1 | KDM4E 201/4885HSD17B10 2529/4885ALOX15 4294/4885 |
| US-20020025960-A1 | Heterocycle carboxamides as antiviral agents | ZC3HAV1, ZC3HAV1L, HDAC1 | KDM4E 201/4885HSD17B10 2529/4885ALOX15 4294/4885 |
| US-20030207880-A1 | Heterocycle carboxamides as antiviral agents | ZC3HAV1, ZC3HAV1L, HDAC1 | KDM4E 201/4885HSD17B10 2529/4885ALOX15 4294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.